Table 1

Demographic, clinical and ultrasonographic data of the study population at baseline

N = 161

Age, years, median (IQR)

64 (50 to 73)

F/M (%)

112/49 (69.6)

Disease duration, months, median (IQR)

3 (2 to 6)

DAS44, mean (± SD)

3.61 (0.96)

SDAI, mean (± SD)

31.53 (13.82)

SJC, median (IQR)

12 (8 to 18)

TJC, median (IQR)

12 (6 to 18)

RAI, median (IQR)

8 (5 to 11)

GH, 0 to 100 mm, median (IQR)

56 (50 to 73)

EGA, 0 to 10 cm, median (IQR)

4.6 (3.5 to 6)

PGA, 0 to 10 cm, median (IQR)

6 (4.8 to 8)

HAQ, median (IQR)

1.25 (0.75 to 1.88)

ESR, mm/h, median (IQR)

28.5 (17 to 46.5)

CRP, mg/dl, median (IQR)

1.19 (0.41 to 3.12)

IgM RF-positive, n. (%)

92 (57.1)

IgM RF titre, UI/ml, median (IQR)

69 (30.5 to 174)

IgG ACPA-positive, n. (%)

79 (49.1)

IgG ACPA titre, UI/ml, median (IQR)

100 (42.7 to 292.5)

US-GS score, median (IQR)

10 (5 to 12)

US-PD positive, n. (%)

122 (75.8)

US-PD score, median (IQR)

3.5 (1 to 8)

ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; DAS44, Disease Activity Score in 44 joints; EGA, evaluator global assessment of disease activity; ESR, erythrocyte sedimentation rate; GH, global health assessment; GS, Grey-Scale; HAQ, Health Assessment Questionnaire; Ig, immunoglobulin; IQR, interquartile range; PD, Power Doppler; PGA, patient global assessment of disease activity; RAI, Ritchie Articular Index; RF, rheumatoid factor; SD, standard deviation; SDAI, Simplified Disease Activity Score; SJC, swollen joint count; TJC, tender joint count; US, ultrasonography

Bugatti et al. Arthritis Research & Therapy 2012 14:R34   doi:10.1186/ar3742